PX-316
PX-316 is an Akt inhibitor. PX-316 can phosphorylate Akt, but does not inhibit the phosphorylation of PDK1 or PKC. PX-316 uniquely increases the expression of a group of mitochondrial-related genes. PX-316 can be used for the study of colon cancer and breast cancer.
For research use only. We do not sell to patients.
- CAS No.: 253440-95-8
- Formula: C28H57O10P
- Molecular Weight:584.72
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
|
Akt |
In Vitro
PX-316 (0-15 μM, 2 h) specifically inhibits Akt (IC50 = 1.7 μM) activation in HT-29 human colon cancer cells without affecting upstream kinase PDK1 or related kinase PKC[1].
PX-316 (0.5-20 μM, 3 days) inhibits the proliferation of MCF-7 and HT-29 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HT-29 human colon cancer cells
-
Concentration:0 μM, 5 μM, 10 μM, 15 μM
-
Incubation Time:2 h
-
Result:Inhibited EGF-induced Akt phosphorylation (phosphorylation of Ser473 site) in a concentration-dependent manner with an IC50 value of 1.7 μM, but did not inhibit PDK1 phosphorylation (Ser241 site) or PKC phosphorylation (Thr638/641 site).
In Vivo
PX-316 (50-150 mg/kg, i.p., once for 4-10 days) demonstrates dose- and regimen-dependent antitumor activity in two different mice xenograft models of human tumors (MCF-7 and HT-29)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:HT-29 colon cancer cells(107)were injected subcutaneously into the flanks of male severe combined immunodeficient (scid) mice[1].
-
Dosage:37.5 mg/kg, 75 mg/kg, 150 mg/kg
-
Administration:I.p., once
-
Result:A single administration of 150 mg/kg inhibited Akt (Ser473) phosphorylation in tumors by up to 78% at 10 hours, recovering to 34% inhibition after 48 hours.
The half-maximal inhibitory dose (ID50) for Akt phosphorylation in tumors was 80 mg/kg, while the ID50 for normal tissue (spleen) was 128 mg/kg.
At a concentration of 150 mg/kg, phosphorylation of GSK-3β (Ser9), a downstream target of Akt, was also inhibited, with inhibition rates of 53% and 77% at 5 hours and 24 hours, respectively.
At a dose of 75 mg/kg, whether administered once daily for 5 consecutive days or once every 3 days for 5 consecutive days, Akt activity was consistently inhibited (inhibition rate of 70%-80%).
-
Animal Model:MCF-7 human breast cancer cells (107 cells) were mixed with Matrigel and subcutaneously injected into the flank of female SCID mice. One day before tumor cell inoculation, mice were subcutaneously implanted with 60-day sustained-release 17-β-estradiol pellets to support the growth of this estrogen-dependent tumor[1].
-
Dosage:50 mg/kg, 75 mg/kg, 100 mg/kg
-
Administration:I.p., once daily for 10 days, 10 days and 5 days, respectively
-
Result:75 mg/kg showed a good inhibitory effect (T/C = 20%), while 100 mg/kg showed a slightly weaker effect (T/C = 39%).
-
Animal Model:HT-29 human colon cancer cells (107 cells) were subcutaneously injected into the flank of SCID mice[1].
-
Dosage:100 mg/kg, 150 mg/kg
-
Administration:I.p., once daily for 4 days
-
Result:Caused growth inhibition of 5-day HT-29 colon cancer xenografts when administered for 4 days IP at 150 mg/kg/day (T/C33.3%, P<0.05) but no activity at 100 mg/kg/day.
-
Chemical Information
-
CAS No. 253440-95-8
-
Molecular Weight 584.72
-
Formula C28H57O10P
-
SMILES
CCCCCCCCCCCCCCCCCCOC[C@@H](OC)COP(O[C@H]1[C@@H]([C@H]([C@@H](C[C@H]1O)O)O)O)(O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)